Alignment Healthcare (NASDAQ:ALHC) disclosed that Chief Operating Officer Sebastian Burzacchi sold 15,361 shares of the company's common stock on March 18, 2026, according to a Form 4 filing with the Securities and Exchange Commission.
The filing shows the shares were sold at a weighted-average price of $17.84, producing a total transaction value of $274,040. The executed prices spanned from $17.40 to $18.24. After the sale, Burzacchi's direct ownership of Alignment Healthcare shares stands at 258,630.
Company stock was trading at $18.16 at the time of the report. The Form 4 filing specifies the disposition was made to satisfy tax withholding obligations associated with the vesting of restricted stock units, and was not a discretionary trade.
Recent operating and financial performance
Alignment Healthcare also reported notable operating results in its fourth quarter. The company recorded approximately 25% year-over-year membership growth and achieved a 44.4% increase in revenue, both figures presented as part of its quarterly results. The medical benefit ratio was reported at 87.7%. Management also highlighted an improvement in the selling, general, and administrative expense ratio to 9.7%.
Broker commentary following those results included Raymond James reiterating a Strong Buy rating with a price target of $27.00, while Piper Sandler maintained an Overweight rating with a $30.00 price target, citing that the medical benefit ratio and adjusted EBITDA exceeded expectations.
Secondary offering underway
In a separate development, Alignment Healthcare announced a secondary offering of 13.2 million shares priced at $19.46 per share. The offering is being made by an affiliate of General Atlantic, L.P., and the company will not receive any proceeds from the sale. J.P. Morgan is acting as underwriter for the offering, which is expected to close on March 4, 2026, subject to customary closing conditions.
Additional market commentary and research notes
Analysis cited in conjunction with the company's market data noted that analysts expect the company to reach profitability this year, with net income forecasted to grow. The company was also characterized by an InvestingPro financial health metric labeled as "GREAT," and InvestingPro tips referenced valuation commentary indicating the stock may be undervalued at current levels. These investment platform observations were presented alongside other analyst views and ratings cited above.
Collectively, the insider filing, quarterly operating metrics and the pending secondary offering present a set of corporate actions and performance indicators that market participants can weigh when assessing Alignment Healthcare's near-term outlook.